PathologyWatch Reinforces Roster of Dermatopathologists with Cacey Peters, MD

Cacey Peters, MD, joins the PathologyWatch team to strengthen the delivery of optimal patient outcomes.

“Combining diagnostic and communication skills with a vast knowledge of whole-slide imaging, Dr. Peters represents a valuable addition to our team of expert dermatopathologists,” says Dan Lambert, cofounder and chief executive officer of PathologyWatch.

Dr. Peters completed his residency in anatomic and clinical pathology at Tulane. His fellowship was in dermatopathology at the Ackerman Academy of Dermatopathology, and he is US-board certified in dermatopathology, anatomic and clinical pathology.

“Streamlining the diagnosis, turnaround time and overall efficiency for dermatologists is crucial to me,” said Dr. Peters. “Joining PathologyWatch will help me to deliver on these goals while also contributing to the team of talented dermatopathologists on challenging cases to benefit the clinicians we serve.”

Dr. Peters comes to PathologyWatch with years of experience promoting digital pathology as a tool to unite and educate both dermatologists and pathologists around the world. “Switching over to primary diagnosis on a digital platform is a dream come true,” said Dr. Peters. “Within my lifetime, I’ve no doubt digital pathology will take over 100% of the industry.”

For more information, please email [email protected] or visit pathologywatch.com.

About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.

PathologyWatch Raises $25M to Advance AI-Driven Skincare Research and Diagnostics

The Series B funding round will help PathologyWatch digitize biopsies, increase access to top skincare physicians and further AI research.

SALT LAKE CITY, November 16, 2021—PathologyWatch, the leading digital lab and pathology platform for dermatologists, announced today that it has raised $25M in Series B financing with participation from Ceros Capital Markets, Rock Creek Capital, SpringTide, Spark Growth Ventures, Blueprint Health, Blackbrook Management Group and existing investors.

With the new funding, PathologyWatch will broaden its outreach to dermatologists and conduct further research into skincare diagnostics and AI – allowing patients to receive faster diagnoses and more equitable access to dermatopathology services while enabling labs to work more efficiently and cost-effectively. Additionally, the funding will support operations as the business expands across the country, adding new labs in Texas, Florida and Arizona.

“We are honored that of all the digital dermpath labs available, dermatologists are increasingly choosing to partner with us,” said Dan Lambert, PathologyWatch CEO and cofounder. “As digital dermatopathology continues to grow, it has the potential to reduce the costs of pathology by billions while creating better patient care for everyone across the country. We’re thrilled to be winning so much volume so quickly.”

PathologyWatch provides fully interfaced EMR reporting and 24/7 access to digital slides for dermatology clinics. For their clients, this means more-efficient workflows and direct access to leading dermatopathologists across the country, with broad insurance coverage. PathologyWatch has successfully integrated laboratory information systems, scanners, digital viewer technology and EMRs into an end-to-end solution for dermatologists.

“PathologyWatch has been disruptive to the market and is digitally transforming the industry in unprecedented ways,” said Mark Goldwasser, CEO of Ceros. “With the need for remote health services during COVID, the distributed network of top-tier dermatopathologists alongside a digital viewer that can be accessed anytime and anywhere could not have come at a more fortuitous time.”

“For a dermatology practice to send nearly all skin biopsy volume for cancer diagnosis to PathologyWatch is a no-brainer,” said Austin Walters, founder and managing partner at SpringTide. “The company has worked hard to create a service that outperforms every other from both cost and quality perspectives.”

“Dan is a driven entrepreneur with social good in mind,” said Ryan Brooks, principal at Blackbrook Management Group. “We are part of a cause, not just an investment capital endeavor. In the past, I have been a patient waiting for pathology to come back. When you are waiting for results that could change your life dramatically, you want doctors and tech you can depend on. PathologyWatch will enhance the human experience and enable dermatopathologists to do a better job.”

“I am proud to support PathologyWatch’s mission to provide premier, accessible and affordable digital pathology services to the world,” said Rick Stratford, managing director of Rock Creek Capital. “The ability to provide top-tier pathology services to all communities regardless of location brings hope to patients in underserved areas and can save countless lives. PathologyWatch and other digital platforms like it are democratizing healthcare services and bringing hope and change to our healthcare systems.”

For more information about PathologyWatch, visit pathologywatch.com or contact [email protected]

About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and in-house lab services. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.

PathologyWatch Boasts Key Addition to Its Roster of Dermatopathologists with Allison Readinger, MD

A leader in dermatology and dermatopathology, Allison Readinger, MD, joins PathologyWatch’s clinical team to assist in the growing landscape of digital healthcare.

Salt Lake City—March 7, 2021—PathologyWatch, a full-service digital pathology service, is pleased to welcome Allison Readinger, MD, to its clinical team. A highly qualified and respected dermatologist and dermatopathologist, Readinger brings a wealth of industry knowledge and innovation, coinciding with PathologyWatch’s mission to preserve and extend life for patients while reducing healthcare costs.

“We are pleased to have Dr. Readinger join us as a member of our clinical team. Her industry expertise and seasoned leadership skills make her a genuine asset,” said Dan Lambert, cofounder and chief executive officer of PathologyWatch. “Together, we are eager to expand our reach across the Texas market, positively impacting the lives of our healthcare providers and their patients.”

An alumnus of the University of Texas Medical Branch at Galveston, Readinger is a board-certified dermatologist and dermatopathologist with over 15 years of experience. In October 2010, she opened Trinity Vista Dermatology to offer more dermatology services to the rapidly growing population of Fort Worth, Texas.

Readinger recently served as President of the Texas Dermatological Society and continues to advocate for patients, for physician and resident education, and for her specialty.

At her core, Readinger enjoys bonding with her patients, providing excellent care, and being at the forefront of advances in medical technology. With an understanding of the importance of attention to detail and personalized care in modern medicine, she makes an excellent addition to the PathologyWatch family.

“I am thrilled to be a part of the continued growth of digital dermatopathology,” said Readinger. “The landscape of digital dermatopathology is growing at a rapid pace, and I am eager to assist in the continued growth and progress of our field.”  She adds, “I hope to utilize digital dermatopathology to expand further my ability to offer great clinicopathologic correlation to my clients.”

For more information, please email [email protected] or visit us at pathologywatch.com.

About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and partner laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.

PathologyWatch Announces Key Hire to Bolster Digital Dermatopathology Practice

Darren Whittemore, DO, joins the PathologyWatch team to support the delivery of optimal patient outcomes.

SALT LAKE CITY—DECEMBER 8, 2020—PathologyWatch, a full-service digital dermatopathology solution, is pleased to welcome Dr. Darren Whittemore, DO, to the growing PathologyWatch family. A qualified and respected dermatopathologist, Whittemore will be instrumental in establishing processes to ensure dermatology clinics receive the highest level of digital pathology services.  

Board certified in anatomic and clinical pathology and dermatopathology, Whittemore was fellowship-trained at the University of Texas Health Science Center after completing his residency at the combined US Air Force Wilford Hall Medical Center/Brooke Army Medical Center program.

“Dermatopathologists play a critical role in a patient’s recommended treatment,” said Dan Lambert, CEO and cofounder of PathologyWatch. “With expertise and attention to detail, Dr. Whittemore utilizes innovative advances in digital pathology to deliver the highest quality of care and efficiency to patients.”

Whittemore brings extensive subspecialty experience and proven abilities in diagnosing alopecia cases to PathologyWatch. Also, he embraces new technologies and the growing role they play in understanding the pathogenesis of diseases. 

“With advantages that include enhanced clinicopathologic correlation, improved turnaround time and paperless, electronic workflows, digital dermatopathology represents the future of the dermatology industry,” Whittemore said. “Joining PathologyWatch places me in the heart of this burgeoning technology with individuals who are committed to helping dermatology clinics deliver industry-leading care to their patients.”

For more information on PathologyWatch, please visit pathologywatch.com.

About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and partner laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.

View the original release.

PathologyWatch Announces Locum Tenens Dermatopathology Services

Full-service lab PathologyWatch now provides remote, academic-level dermatopathology services to laboratories in need of temporary or long-term support.

Digital dermatopathology service provider PathologyWatch is now offering top-tier dermatopathology services to laboratories in need of temporary or long-term locum tenens support. Utilizing the advantages of digital pathology, PathologyWatch provides instant remote access to a workforce of academic-level dermatopathologists.

Commonly, a laboratory in need of locum tenens assistance is responsible for providing travel arrangements, lodging and per diem to attract qualified talent. Using an integrated digital pathology system, PathologyWatch eliminates costly overhead by offering a network of expert dermatopathologists available 24/7 for consultation. As a result, laboratories find a seamless transition to help them to continue running at full capacity.

“Providing locum tenens support to companies experiencing overflow due to staffing or seasonal variables is the next logical step for PathologyWatch,” says CEO and co-founder Dan Lambert. “Our locums tenens support is ideal for pathology labs and dermatology clinics that have a limited number of in-house dermatopathologists. The on-demand services require no minimum or advanced notice. When dermatopathologists have an influx of samples, have a life event, or even want to take a vacation, they can simply turn on the services for as long as they need them.”

In addition to a significant reduction in travel costs, PathologyWatch provides labs with 24/7 digital access to all pathology slides without purchasing a scanner. This also includes improved access to subspecialists and second opinions. Meanwhile, extensive insurance coverage means PathologyWatch can accommodate the majority of laboratory customers nationwide.

“Using PathologyWatch for locums coverage has given me access to high-quality dermatopathologists when I needed the coverage with ease and flexibility,” said Emily Green, dermatopathology lab director at Golden State Dermatology. “I highly recommend their services.”

For more information on PathologyWatch, please visit PathologyWatch.com. PathologyWatch follows all state and federal regulations. As such, the specific coverage arrangement may vary from state to state.

About PathologyWatch

PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhance patient outcomes by utilizing the PathologyWatch expert professional team and partner laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision making to deliver unprecedented patient care.

PathologyWatch Raises $5M in Series A Funding to Speed Adoption of Digital Dermatopathology Solutions

Funding Led by SpringTide Investments and Rock Creek Capital

SALT LAKE CITY, MAY 11, 2020—PathologyWatch announced today a $5M series A funding led by SpringTide Investments and Rock Creek Capital with additional funding by individual investors. PathologyWatch is emerging as the groundbreaking leader of intuitive, easy-to-implement digital dermatopathology solutions that can speed the diagnostic process while reducing costs to clinics and enhancing patient care.

PathologyWatch will utilize this series A funding to strengthen outreach to dermatology clinics nationwide. Over 12 months, it expects to triple its sales force while expanding marketing efforts and implementing a strong channel partner strategy. The funding also represents a continued investment in the development of technology and supervised artificial intelligence (AI) for various cancer lines.

PathologyWatch differentiates itself from competitors by offering fully interfaced EMR (Electronic Medical Records) reporting and 24/7 access to digital slides. Clients also have access to top dermatopathologists and the option to interpret and bill for their cases. PathologyWatch is further distinct by its primary focus on outpatient clinics.

Changing “How Pathology Operates by Transforming Biopsy Diagnostics”

“We believe PathologyWatch will change how pathology operates by transforming biopsy diagnostics,” said Austin Waters, principal at SpringTide Investments. “PathologyWatch has created a platform to digitize pathology workflows and is a leading developer of AI algorithms that detect and characterize cancers from biopsy samples. The quality and breadth of their solution, and their early success in dermatopathology, is why we’re bullish on the future of this company; PathologyWatch is redefining biopsy diagnostics as we know it.”

First Live Clinical Implementation of Dermatopathology AI with Ability to Generate Complete Reports

“We have the first live clinical implementation of dermatopathology AI that can generate a full report and make physicians significantly more efficient in Australia, as we’re working alongside physicians to better diagnose skin cancer,” said PathologyWatch co-founder and CEO Dan Lambert. 

Benefits the Patient by Merging Clinical Observations with Pathology

“PathologyWatch is a game changer,” said Jeffrey Smith, Dermatologist, Prairie Lakes Healthcare System. “Digital access to my cases, expert dermpath reads, and an EMR interface– not to mention the time savings and increase in revenue for our hospital, all while keeping our patients in-network. Most importantly, this benefits the patient by merging clinical observations with pathology.”*

The “Future of Dermatopathology for Dermatologists”

“I believe PathologyWatch is the future of dermatopathology for dermatologists. The group combines academic expertise with the efficiency of a private lab. It is a huge timesaver for me and my staff,” said April Larson, Dermatologist. “By reviewing my own cases, I am able to make better clinical decisions for my patients. It’s a win-win for everybody.”

For more information on PathologyWatch, please visit pathologywatch.com.

About PathologyWatch

PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through two programs, ValueWatch and BusinessWatch, dermatology clinics and hospitals can improve operational efficiency by speeding up workflow and improve patient outcomes by utilizing the PathologyWatch expert professional team and partner laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology.* With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision making to deliver unprecedented patient care.

About SpringTide Investments

SpringTide is a network of experienced healthcare founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality healthcare.

About Rock Creek Capital

A venture and equity investment firm, Rock Creek Capital is a Utah-based fund. Focused on growth equity, the fund helps entrepreneurs and founders of companies scale successfully.